RESMED INC US false 0000943819 0000943819 2024-11-20 2024-11-20

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

November 20, 2024

Date of Report (Date of earliest event reported)

 

 

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-15317   98-0152841

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

9001 Spectrum Center Boulevard

San Diego, California 92123

(Address of Principal Executive Offices) (Zip Code)

(858) 836-5000

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.004 par value   RMD   NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter) ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

 

 

 

Item 5.07.

Submission of Matters to a Vote of Security Holders.

On November 20, 2024, at our annual meeting of stockholders, our stockholders (1) elected the eleven nominees listed below to serve on our board of directors; (2) ratified the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2025; and (3) approved, on an advisory basis, the compensation of our named executive officers (“say-on-pay”).

 

     For      Against      Abstain      Broker
Non-Votes		  

Item of business 1: Elect the following eleven directors, each to serve until our 2025 annual meeting and until their successors are elected and qualified:

            

Carol Burt

      105,566,293        4,609,884        81,094        4,969,328  

Christopher DelOrefice

      109,836,913        337,767        82,591        4,969,328  

Jan De Witte

      109,745,710        430,055        81,506        4,969,328  

Karen Drexler

      101,135,602        9,042,745        78,924        4,969,328  

Michael Farrell

      105,058,243        4,724,177        474,851        4,969,328  

Peter Farrell

      107,590,325        2,605,639        61,307        4,969,328  

Harjit Gill

      109,303,018        871,110        83,143        4,969,328  

John Hernandez

      109,431,549        743,605        82,117        4,969,328  

Richard Sulpizio

      88,007,747        22,003,356        246,168        4,969,328  

Desney Tan

      109,241,632        934,672        80,967        4,969,328  

Ronald Taylor

      95,465,730        14,705,330        86,211        4,969,328  
     For      Against      Abstain      Broker
Non-Votes		  

Item of business 2: Ratify our selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2025.

      105,082,628        10,096,722        47,249     
     For      Against      Abstain      Broker
Non-Votes		  

Item of business 3: Approve, on an advisory basis, the compensation of our named executive officers, as disclosed in our proxy statement (“say-on-pay”).

      92,885,004        17,284,647        87,620        4,969,328  

SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

 

  RESMED INC.
Date: November 21, 2024   By:  

/s/ Michael Rider

    Michael Rider
    Chief Legal Officer, Global General Counsel and Secretary
v3.24.3
Document and Entity Information
Nov. 20, 2024
Cover [Abstract]  
Entity Registrant Name RESMED INC
Entity Address, Country US
Amendment Flag false
Entity Central Index Key 0000943819
Document Type 8-K
Document Period End Date Nov. 20, 2024
Entity Incorporation State Country Code DE
Entity File Number 001-15317
Entity Tax Identification Number 98-0152841
Entity Address, Address Line One 9001 Spectrum Center Boulevard
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92123
City Area Code (858)
Local Phone Number 836-5000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.004 par value
Trading Symbol RMD
Security Exchange Name NYSE
Entity Emerging Growth Company false
ResMed (NYSE:RMD)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more ResMed Charts.
ResMed (NYSE:RMD)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more ResMed Charts.